Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
|Articles|July 13, 2021
Share A Mental Health Minute
Author(s)Psychiatric Times Editors
Can you spare a minute to share your insights?
Advertisement
Psychiatric TimesTM shares insights, commentaries, practice tips, and research reviews from leaders in psychiatry and clinicians like yourself.
Are you interested in sharinga Mental Health Minute of your own? Write to us at
Advertisement
Related to this article
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Preventing Schizophrenia Relapse in Women: What You Need to Know
5